New Contract Research and Manufacturing Firm BioDuro Launches
The new company is the product of a merger with Formex.
BioDuro announced its official launch as a new company during the Biotechnology Innovation Organization (BIO) meeting in June 2016, focusing on its new identity as a full-service preclinical research and clinical development service provider. Prior to a recent merger with Formex, BioDuro focused mostly on early clinical development.
As a result of the merger, BioDuro adds expertise in formulation, development, and manufacture of drug product. It will offer bioavailability enhancement services for poorly soluble compounds and scale-up services for the preclinical and clinical manufacture of drug products.
Customers will also now have access to an additional 44,000 square feet of cGMP manufacturing space in San Diego. BioDuro has an existing 100,000-square-foot facility in Beijing, which serves as a biosimilar services hub focused on formulation and bioequivalence studies, as well as a center for synthetic chemistry; and a 92,000-square-foot facility in Shanghai dedicated to the company’s drug screening, bioanalysis, pharmacokinetic and pharmacodynamic studies, biomarker identification, and traditional research activities.
Source: BioDuro
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
